title: [The significance of gestagens in treatment of mastopathy].
abstract: The term "mastopathy" has yet to receive a common accepted definition. 70% of all mastopathies do not demonstrate, morphologically speaking, a proliferation, where as less than 10% show an atypical proliferation that suggests an increased risk for cancer development. The indication for the treatment of a mastopathy without proliferative processes is the existence of pain. The concurrent development of Hyperprolactinemia, Hyperandrogenemia, or Hypothyreosis and the resulting metabolic disorders that accompany such should be treated in a causal manner. Progestins have proved to be effective in cases where a progesterone deficit and/or a relative hyperestrogenism exist. An evaluation of progestins as a prophylaxis for breast carcinoma development in women with an atypical proliferation, however, can first be completed when a deeper knowledge of the local hormone situation in the breast tissue exists. Suitable in this case, are the 17-Hydroxyprogesterone derivatives, because the 19-Nortestosterone derivatives produce a negative influence on the Lipid metabolism due to their partial androgenic effect and in addition, antagonise the hepatocellular estrogen effect (IGF1-reduction and SHBG-increase), which may indirectly offer protection for the breast.
authors.affiliation: Kreiskrankenhaus Ammerland, Westerstede.
authors.forename: K W
authors.initials: KW
authors.lastname: Schweppe
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy*; D006801:Humans; D011230:Precancerous Conditions / Q000188:drug therapy*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D045167:Progesterone Congeners